Commentary

Video

Dr Li on the Rationale of the MoonRISe-1 Trial in NMIBC

Author(s):

Roger Li, MD
Conference|American Urological Association Annual Meeting

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).

Roger Li, MD, a genitourinary oncologist at Moffitt Cancer Center, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820) examining TAR-210 vs intravesical chemotherapy in patients with non–muscle-invasive bladder cancer.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Roger Li, MD,
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Antonio Cigliola, MD
Related Content
Sonya Reid, MD, MPH
July 22nd 2024

Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Pedram Razavi, MD, PhD
July 22nd 2024

Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Hope S. Rugo, MD, of University of California, San Francisco
July 19th 2024

AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer

Richard Kim, MD
July 19th 2024

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC